Market Overview

Bernstein Weighs In On Vertex Move

Related VRTX
Midday Gainers From September 19 - Alibaba Group Holding Ltd, Concur Technologies, Inc. And More
Benzinga's Top Upgrades

As shares of Vertex Pharmaceuticals (NASDAQ: VRTX) have rallied over 40 percent following a press release concerning phase 3 studies of its Lumacaftor Ivacaftor combination regime, Bernstein analyst Geoffrey Porges issued a note with his take on the stock

Despite Tuesday's move, Porges maintained his Market Perform rating and $65 price target.

Porges noted the data are "clearly better than expected," but believes the immediate potential of the combination is substantially priced in. Moreover, he thinks short-covering will initially exaggerate the move.

Looking forward, Porges expects the regimen to receive FDA approval.

For a more detailed look into the press release, click here.

Latest Ratings for VRTX

DateFirmActionFromTo
Sep 2014Deutsche BankMaintainsBuy
Sep 2014Deutsche BankMaintainsBuy
Sep 2014Goldman SachsUpgradesNeutralBuy

View More Analyst Ratings for VRTX
View the Latest Analyst Ratings

Posted-In: Bernstein Geoffrey PorgesAnalyst Color News Price Target Reiteration Analyst Ratings

 

Related Articles (VRTX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters